Streetwise Reports' Article Archives — December 2021 back to current month (25)
Analyst: Drug a 'Hidden Gem for 2022' (12/31/2021)
Oppenheimer ranks Astria Therapeutics Outperform after learning about its drug for hereditary angioedema, saying "We stay bullish."
Co.'s COVID-19 Test Detects Omicron Variant (12/30/2021)
H.C. Wainwright & Co. gives Sorrento Therapeutics a Buy rating after initial testing shows its COVISTIX detects COVID-19's Omicron variant.
Co. Looks To US For Help Fighting Strokes (12/29/2021)
Canadian company Algernon Pharmaceuticals Inc. has applied to uplist to the Nasdaq in hopes of attracting U.S. investors to its mission to repurpose drugs.
Co. Still Compelling After Drug Trial Failure (12/29/2021)
"Arcalyst remains the value driver" for Kiniksa Pharmaceuticals, and "we continue to hold a favorable view of the company," noted a Wedbush report.
"Cytokinetics' pipeline of muscle-directed therapies has potential to address several diseases with high unmet medical need and may generate significant revenue across pipeline programs," noted an Oppenheimer report.
A DawsonJames report notes that Brainstorm Cell Therapeutics’ autologous stem cells in amyotrophic lateral sclerosis will need further study to prove their effectiveness.
"With Acasti Pharma shares trading near cash levels yet current resources sufficient to achieve key development milestones across the pipeline over 2022-2023, we recommend investors build a position," noted an Oppenheimer report.
Analyst Highlights Top Picks in Biotech for 2022 (12/20/2021)
Aldeyra Therapeutics, in the ophthalmology space, and SQZ Biotechnologies, in the cell therapy sector, have "advantages that their specific approaches allow," noted a BTIG report.
Intra-Cellular Therapies Inc. shares traded 19% higher to a new 52-week high after the company reported the U.S. FDA has approved the use of its CAPLYTA® (lumateperone) for treatment of adults with bipolar depression.
BioXcel Therapeutics' lead drug candidate for agitation in Alzheimer's disease patients could serve a substantial market, noted an H.C. Wainwright & Co. report.
Analyst Says Regeneron Could Be 'Biotech Champion' (12/17/2021)
Regeneron Pharmaceuticals Inc.'s stock was up 36% in 2021 while the NASDAQ Biotechnology Index remained flat, Oppenheimer analyst Hartaj Singh reported in a Dec. 16 research note.
Co.'s Shares Gain 27% After FDA Nears Drug Approval (12/16/2021)
Shares of Calliditas Therapeutics AB traded higher after the company reported the U.S. FDA granted accelerated approval for its TARPEYO™ (budesonide) to reduce proteinuria in IgA nephropathy.
During its recent R&D Day, Prometheus Biosciences announced new strong trial data, another new indication for its lead therapeutic candidate and progress in developing a subcutaneous formulation of it, according to an Oppenheimer report.
Arena Pharmaceuticals shares traded 80% higher after the company reported it agreed to be acquired by Pfizer Inc. for $100.00 per share in cash in a deal valued at $6.7 billion.
F-star Therapeutics "has methodically delivered scientific/preclinical/early clinical data validating its platform bispecific technology," noted an Oppenheimer report.
Checkpoint Therapeutics' "cosibelimab represents a competitive asset on both efficacy and safety with an expected added advantage of lower net price," an H.C. Wainwright & Co. report noted.
The partnership allows Hansa Biopharma to "enter new markets without the cost and risk of building out country-specific commercial organizations for a single product," an H.C. Wainwright & Co. report indicated.
Humanigen has applications for lenzilumab in the works with U.S., United Kingdom and European drug regulatory agencies, noted a ROTH Capital Partners report.
Shares of contract research organization Inotiv Inc. traded higher after the company reported select preliminary unaudited financial results for Q4/21 and FY/21 which included a 90.7% YoY increase in revenue and a 123.0% increase in gross profit.
Harmony Biosciences Holdings intends to conduct a Phase Three trial next year to evaluate Wakix as a treatment for idiopathic hypersomnia, according to an Oppenheimer report.
Shares of pet healthcare insurer Trupanion Inc. reached a new 52-week high after the company reported it is teaming up with Chewy Inc. to offer an exclusive line of pet wellness and health insurance products to Chewy's 20,000,000 customers.
Sensus Healthcare's "needle-free treatment presents a clear competitive advantage in the aesthetic dermatology space," an H.C. Wainwright & Co. report noted.
New clinical trials for G1 Therapeutics’ Cosela are “central to our investment thesis,” H.C. Wainright & Co. noted in a new research report.
"Solid tumors offers a substantial opportunity for Karyopharm Therapeutics' Xpovio (selinexor) that perhaps investors have not yet realized," noted an H.C. Wainwright & Co. report.
Adicet Bio Inc. shares traded 37% higher after the company reported positive interim data from its Phase 1 GLEAN Study of ADI-001, which the firm noted is the first-ever allogeneic, off-the-shelf, gamma delta CAR T investigational cell therapy.
|"Data presented by peers at the CTAD conference are relevant to PMN."|